179114-90-0Relevant articles and documents
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis- 6-Methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e]isoindol-2- yl)ethyl]pyrido[3',4':4,5]thieno[3,2,d]pyrimidine-2,4(1H,3H)-dione (a- 131701): A uroselective α(1A) adrenoceptor antagonist for
Meyer,Altenbach,Basha,Carroll,Drizin,Elmore,Ehrlich,Lebold,Tietje,Sippy,Wendt,Plata,Plagge,Buckner,Brune,Hancock,Kerwin J.F.
, p. 3141 - 3143 (1997)
Pharmacological management of benign prostatic hyperplasia (BPH) has most successfully been achieved by administration of α1 antagonists, which function via relaxation of prostatic smooth muscle. Terazosin2 (2), doxazosin3